| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diphosphonates | 23 | 2026 | 64 | 7.310 |
Why?
|
| Osteoporotic Fractures | 14 | 2026 | 42 | 6.780 |
Why?
|
| Bone Density Conservation Agents | 20 | 2026 | 55 | 6.680 |
Why?
|
| Osteoporosis | 18 | 2026 | 75 | 5.780 |
Why?
|
| Bone Density | 19 | 2025 | 96 | 4.810 |
Why?
|
| Hip Fractures | 14 | 2025 | 74 | 4.140 |
Why?
|
| Female | 164 | 2026 | 12715 | 3.690 |
Why?
|
| Humans | 194 | 2026 | 17622 | 3.540 |
Why?
|
| Aged | 98 | 2026 | 6223 | 3.250 |
Why?
|
| Femoral Fractures | 7 | 2025 | 23 | 3.040 |
Why?
|
| Middle Aged | 120 | 2026 | 7954 | 2.930 |
Why?
|
| Breast Neoplasms | 27 | 2021 | 1005 | 2.780 |
Why?
|
| Fractures, Bone | 12 | 2026 | 93 | 2.620 |
Why?
|
| Polycystic Ovary Syndrome | 6 | 2022 | 18 | 2.460 |
Why?
|
| Risk Factors | 57 | 2026 | 3291 | 2.380 |
Why?
|
| Aged, 80 and over | 39 | 2026 | 1976 | 2.360 |
Why?
|
| California | 47 | 2026 | 2433 | 2.280 |
Why?
|
| Retrospective Studies | 35 | 2025 | 2502 | 2.050 |
Why?
|
| Male | 90 | 2026 | 10014 | 2.020 |
Why?
|
| Asian Americans | 12 | 2022 | 160 | 1.980 |
Why?
|
| Overweight | 10 | 2026 | 266 | 1.840 |
Why?
|
| Risk Assessment | 29 | 2025 | 1093 | 1.840 |
Why?
|
| Kidney Failure, Chronic | 11 | 2019 | 149 | 1.820 |
Why?
|
| Diabetes, Gestational | 12 | 2026 | 328 | 1.820 |
Why?
|
| Pediatric Obesity | 8 | 2026 | 101 | 1.790 |
Why?
|
| Prevalence | 21 | 2025 | 830 | 1.710 |
Why?
|
| Vitamin D | 5 | 2024 | 76 | 1.600 |
Why?
|
| Delivery of Health Care, Integrated | 10 | 2025 | 540 | 1.540 |
Why?
|
| Renal Dialysis | 7 | 2019 | 57 | 1.490 |
Why?
|
| Adult | 78 | 2026 | 7621 | 1.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2025 | 689 | 1.460 |
Why?
|
| Obesity | 13 | 2025 | 821 | 1.440 |
Why?
|
| Cohort Studies | 40 | 2025 | 2502 | 1.420 |
Why?
|
| Medication Adherence | 4 | 2019 | 232 | 1.380 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2021 | 65 | 1.360 |
Why?
|
| Body Mass Index | 23 | 2026 | 959 | 1.360 |
Why?
|
| Incidence | 21 | 2025 | 1278 | 1.300 |
Why?
|
| Diabetes Mellitus | 9 | 2024 | 452 | 1.170 |
Why?
|
| Vitamin D Deficiency | 4 | 2024 | 24 | 1.170 |
Why?
|
| Obesity, Morbid | 3 | 2024 | 121 | 1.150 |
Why?
|
| Prediabetic State | 3 | 2025 | 62 | 1.120 |
Why?
|
| Cross-Sectional Studies | 21 | 2025 | 1295 | 1.110 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 383 | 1.100 |
Why?
|
| HIV Infections | 14 | 2023 | 584 | 1.100 |
Why?
|
| Pregnancy Complications | 5 | 2017 | 208 | 1.100 |
Why?
|
| Ethnic Groups | 7 | 2017 | 443 | 1.090 |
Why?
|
| Age Factors | 18 | 2018 | 874 | 1.060 |
Why?
|
| Jaw Diseases | 4 | 2011 | 8 | 1.020 |
Why?
|
| Osteonecrosis | 4 | 2011 | 9 | 1.020 |
Why?
|
| European Continental Ancestry Group | 9 | 2020 | 470 | 1.020 |
Why?
|
| United States | 25 | 2026 | 3922 | 0.960 |
Why?
|
| Prospective Studies | 33 | 2026 | 1251 | 0.950 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2019 | 248 | 0.950 |
Why?
|
| Renal Insufficiency, Chronic | 10 | 2019 | 187 | 0.930 |
Why?
|
| Adolescent | 23 | 2025 | 3625 | 0.930 |
Why?
|
| Follow-Up Studies | 20 | 2020 | 1157 | 0.920 |
Why?
|
| Child | 19 | 2026 | 2485 | 0.920 |
Why?
|
| Cardiovascular Diseases | 7 | 2021 | 545 | 0.910 |
Why?
|
| Hypothyroidism | 3 | 2017 | 6 | 0.880 |
Why?
|
| Osteoporosis, Postmenopausal | 5 | 2025 | 43 | 0.870 |
Why?
|
| Electronic Health Records | 6 | 2024 | 719 | 0.860 |
Why?
|
| Patient Portals | 1 | 2024 | 23 | 0.850 |
Why?
|
| Time Factors | 19 | 2026 | 1038 | 0.830 |
Why?
|
| Premature Birth | 3 | 2015 | 136 | 0.810 |
Why?
|
| Alendronate | 5 | 2012 | 15 | 0.800 |
Why?
|
| Aromatase Inhibitors | 4 | 2020 | 33 | 0.800 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 168 | 0.780 |
Why?
|
| Pregnancy | 22 | 2026 | 1565 | 0.770 |
Why?
|
| Survivors | 9 | 2013 | 157 | 0.760 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 7 | 0.760 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 33 | 0.740 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 35 | 0.740 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 50 | 0.730 |
Why?
|
| Chronic Disease | 6 | 2019 | 398 | 0.720 |
Why?
|
| Primary Health Care | 3 | 2025 | 729 | 0.710 |
Why?
|
| Thyroid Gland | 3 | 2019 | 6 | 0.700 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2026 | 205 | 0.690 |
Why?
|
| Insulin Resistance | 8 | 2014 | 128 | 0.690 |
Why?
|
| Breast Feeding | 5 | 2026 | 119 | 0.690 |
Why?
|
| Surveys and Questionnaires | 12 | 2024 | 1296 | 0.680 |
Why?
|
| Research Personnel | 1 | 2021 | 28 | 0.680 |
Why?
|
| Continental Population Groups | 4 | 2016 | 283 | 0.670 |
Why?
|
| Hypertension | 8 | 2017 | 486 | 0.660 |
Why?
|
| Hyperprolactinemia | 2 | 2020 | 3 | 0.660 |
Why?
|
| Kidney Diseases | 5 | 2011 | 54 | 0.650 |
Why?
|
| Internship and Residency | 2 | 2019 | 58 | 0.650 |
Why?
|
| Oceanic Ancestry Group | 2 | 2019 | 32 | 0.650 |
Why?
|
| Metatarsal Bones | 1 | 2020 | 1 | 0.640 |
Why?
|
| Ankle Fractures | 1 | 2020 | 1 | 0.640 |
Why?
|
| Asthma | 1 | 2023 | 401 | 0.630 |
Why?
|
| Biomarkers | 9 | 2020 | 302 | 0.630 |
Why?
|
| Administration, Oral | 8 | 2020 | 84 | 0.620 |
Why?
|
| Fractures, Spontaneous | 1 | 2019 | 3 | 0.620 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2019 | 5 | 0.610 |
Why?
|
| Contraceptive Agents, Female | 1 | 2019 | 12 | 0.610 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2019 | 15 | 0.610 |
Why?
|
| Contraceptives, Oral | 1 | 2019 | 25 | 0.610 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 109 | 0.590 |
Why?
|
| Child, Preschool | 13 | 2026 | 1455 | 0.590 |
Why?
|
| Adipose Tissue | 6 | 2004 | 67 | 0.590 |
Why?
|
| Hispanic Americans | 5 | 2017 | 370 | 0.590 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 36 | 0.580 |
Why?
|
| African Americans | 6 | 2017 | 429 | 0.570 |
Why?
|
| Treatment Outcome | 8 | 2019 | 1161 | 0.570 |
Why?
|
| Glomerular Filtration Rate | 11 | 2023 | 158 | 0.550 |
Why?
|
| Young Adult | 17 | 2020 | 2538 | 0.540 |
Why?
|
| Lymphedema | 3 | 2012 | 8 | 0.530 |
Why?
|
| Thinness | 2 | 2015 | 31 | 0.530 |
Why?
|
| Nutritional Sciences | 1 | 2017 | 9 | 0.520 |
Why?
|
| Teaching | 1 | 2017 | 15 | 0.520 |
Why?
|
| Internal Medicine | 1 | 2017 | 22 | 0.520 |
Why?
|
| Thyroid Function Tests | 1 | 2017 | 2 | 0.520 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 25 | 0.510 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 5 | 0.510 |
Why?
|
| Drug Prescriptions | 4 | 2026 | 143 | 0.500 |
Why?
|
| Quality of Life | 8 | 2024 | 505 | 0.480 |
Why?
|
| Prehypertension | 2 | 2013 | 21 | 0.480 |
Why?
|
| Accidental Falls | 6 | 2019 | 50 | 0.480 |
Why?
|
| China | 5 | 2020 | 132 | 0.470 |
Why?
|
| Absorptiometry, Photon | 4 | 2025 | 54 | 0.470 |
Why?
|
| Blood Glucose | 10 | 2025 | 319 | 0.460 |
Why?
|
| Gait | 5 | 2018 | 8 | 0.460 |
Why?
|
| Body Composition | 7 | 2004 | 92 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2026 | 308 | 0.460 |
Why?
|
| Pregnancy Outcome | 4 | 2012 | 162 | 0.450 |
Why?
|
| Thyrotoxicosis | 1 | 2015 | 2 | 0.450 |
Why?
|
| Antithyroid Agents | 1 | 2015 | 3 | 0.450 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 350 | 0.450 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 9 | 0.450 |
Why?
|
| Congenital Abnormalities | 1 | 2015 | 27 | 0.450 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 51 | 0.450 |
Why?
|
| Transition to Adult Care | 1 | 2015 | 11 | 0.440 |
Why?
|
| Dizziness | 3 | 2019 | 3 | 0.430 |
Why?
|
| Osteosclerosis | 2 | 2012 | 2 | 0.420 |
Why?
|
| Postural Balance | 4 | 2019 | 14 | 0.420 |
Why?
|
| Algorithms | 2 | 2017 | 227 | 0.410 |
Why?
|
| Earthquakes | 1 | 2013 | 2 | 0.410 |
Why?
|
| Databases, Factual | 5 | 2019 | 304 | 0.400 |
Why?
|
| Bereavement | 1 | 2013 | 8 | 0.400 |
Why?
|
| Health Behavior | 1 | 2016 | 348 | 0.400 |
Why?
|
| Menopause | 5 | 2019 | 68 | 0.400 |
Why?
|
| Lactation | 5 | 2015 | 38 | 0.400 |
Why?
|
| Pediatrics | 1 | 2015 | 149 | 0.400 |
Why?
|
| Independent Living | 2 | 2024 | 24 | 0.390 |
Why?
|
| Postmenopause | 5 | 2017 | 251 | 0.390 |
Why?
|
| Parenting | 1 | 2013 | 30 | 0.380 |
Why?
|
| Hospitalization | 5 | 2022 | 831 | 0.380 |
Why?
|
| Health Services | 1 | 2013 | 110 | 0.370 |
Why?
|
| Family | 1 | 2013 | 111 | 0.370 |
Why?
|
| Cervix Uteri | 1 | 2012 | 5 | 0.370 |
Why?
|
| Uterine Cervical Diseases | 1 | 2012 | 2 | 0.370 |
Why?
|
| Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 | 2012 | 1 | 0.370 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 10 | 0.370 |
Why?
|
| Infant | 11 | 2026 | 1228 | 0.370 |
Why?
|
| HIV Protease Inhibitors | 8 | 2007 | 19 | 0.360 |
Why?
|
| Anti-HIV Agents | 5 | 2023 | 120 | 0.360 |
Why?
|
| Tamoxifen | 2 | 2017 | 55 | 0.360 |
Why?
|
| Perimenopause | 1 | 2011 | 11 | 0.350 |
Why?
|
| Blood Pressure | 5 | 2019 | 288 | 0.350 |
Why?
|
| Mouth Diseases | 1 | 2011 | 3 | 0.340 |
Why?
|
| Oral Health | 1 | 2011 | 17 | 0.340 |
Why?
|
| Diabetic Retinopathy | 3 | 2019 | 17 | 0.340 |
Why?
|
| Infant, Newborn | 9 | 2026 | 842 | 0.330 |
Why?
|
| Postpartum Period | 3 | 2025 | 93 | 0.330 |
Why?
|
| Femur Neck | 2 | 2025 | 6 | 0.330 |
Why?
|
| Prognosis | 12 | 2020 | 609 | 0.330 |
Why?
|
| Heart Failure | 3 | 2025 | 414 | 0.320 |
Why?
|
| Dental Implantation, Endosseous | 1 | 2010 | 1 | 0.320 |
Why?
|
| Dental Implants | 1 | 2010 | 1 | 0.320 |
Why?
|
| Dental Restoration Failure | 1 | 2010 | 1 | 0.320 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2001 | 6 | 0.320 |
Why?
|
| Health Promotion | 1 | 2013 | 293 | 0.320 |
Why?
|
| Glucose Intolerance | 2 | 2025 | 46 | 0.320 |
Why?
|
| Cholesterol, LDL | 3 | 2016 | 117 | 0.310 |
Why?
|
| Insulin | 9 | 2012 | 188 | 0.300 |
Why?
|
| Retinal Diseases | 3 | 2015 | 17 | 0.300 |
Why?
|
| Japan | 2 | 2020 | 14 | 0.290 |
Why?
|
| Philippines | 2 | 2020 | 25 | 0.290 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2006 | 27 | 0.290 |
Why?
|
| Cholesterol, HDL | 2 | 2014 | 68 | 0.290 |
Why?
|
| Estrogen Receptor alpha | 2 | 2015 | 25 | 0.290 |
Why?
|
| Disease Progression | 9 | 2019 | 266 | 0.280 |
Why?
|
| Alcohol Drinking | 2 | 2012 | 354 | 0.280 |
Why?
|
| Curriculum | 2 | 2019 | 54 | 0.280 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2009 | 8 | 0.280 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2005 | 22 | 0.270 |
Why?
|
| Diet | 4 | 2019 | 355 | 0.270 |
Why?
|
| Human Growth Hormone | 3 | 2002 | 5 | 0.270 |
Why?
|
| Growth Hormone | 2 | 2004 | 2 | 0.260 |
Why?
|
| Lactic Acid | 3 | 2007 | 10 | 0.260 |
Why?
|
| Femur | 2 | 2020 | 10 | 0.260 |
Why?
|
| Fasting | 3 | 2005 | 46 | 0.250 |
Why?
|
| Age Distribution | 4 | 2016 | 230 | 0.250 |
Why?
|
| Secondary Prevention | 2 | 2025 | 50 | 0.250 |
Why?
|
| Women's Health | 3 | 2019 | 198 | 0.240 |
Why?
|
| Receptors, Progesterone | 2 | 2015 | 50 | 0.240 |
Why?
|
| Proportional Hazards Models | 9 | 2020 | 702 | 0.240 |
Why?
|
| Sex Distribution | 3 | 2024 | 174 | 0.240 |
Why?
|
| Glucose Tolerance Test | 6 | 2025 | 108 | 0.240 |
Why?
|
| Patient Compliance | 2 | 2017 | 269 | 0.240 |
Why?
|
| Child Development | 1 | 2026 | 57 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 33 | 0.230 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2017 | 5 | 0.230 |
Why?
|
| Emergency Medical Services | 2 | 2017 | 44 | 0.230 |
Why?
|
| Lipids | 6 | 2019 | 69 | 0.230 |
Why?
|
| Maternal Age | 2 | 2017 | 74 | 0.230 |
Why?
|
| Periprosthetic Fractures | 1 | 2025 | 1 | 0.220 |
Why?
|
| Risk | 5 | 2019 | 492 | 0.220 |
Why?
|
| Fibroblast Growth Factors | 3 | 2019 | 13 | 0.220 |
Why?
|
| Bone Resorption | 2 | 2016 | 4 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 369 | 0.220 |
Why?
|
| Hydatidiform Mole | 1 | 2004 | 1 | 0.220 |
Why?
|
| Hyperthyroidism | 1 | 2004 | 1 | 0.220 |
Why?
|
| Chorionic Gonadotropin | 1 | 2004 | 2 | 0.220 |
Why?
|
| Asian Continental Ancestry Group | 4 | 2013 | 87 | 0.220 |
Why?
|
| Uterine Neoplasms | 1 | 2004 | 14 | 0.220 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2004 | 1 | 0.220 |
Why?
|
| Drug Utilization | 1 | 2025 | 119 | 0.210 |
Why?
|
| Fatigue | 2 | 2022 | 30 | 0.210 |
Why?
|
| Home Care Services | 2 | 2018 | 34 | 0.210 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 99 | 0.200 |
Why?
|
| Severity of Illness Index | 7 | 2014 | 446 | 0.200 |
Why?
|
| Retinal Vessels | 3 | 2019 | 5 | 0.200 |
Why?
|
| Logistic Models | 7 | 2015 | 866 | 0.200 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 7 | 0.200 |
Why?
|
| Ritonavir | 4 | 2007 | 14 | 0.190 |
Why?
|
| HIV-1 | 3 | 2007 | 57 | 0.190 |
Why?
|
| Retina | 2 | 2015 | 25 | 0.190 |
Why?
|
| Poverty | 1 | 2024 | 171 | 0.190 |
Why?
|
| Diabetic Nephropathies | 1 | 2023 | 25 | 0.190 |
Why?
|
| Odds Ratio | 7 | 2020 | 631 | 0.190 |
Why?
|
| Body Constitution | 2 | 2001 | 39 | 0.190 |
Why?
|
| Hypertensive Retinopathy | 2 | 2012 | 3 | 0.190 |
Why?
|
| Hospice Care | 1 | 2002 | 9 | 0.180 |
Why?
|
| Thyroxine | 2 | 2019 | 7 | 0.180 |
Why?
|
| Metabolic Syndrome | 3 | 2008 | 64 | 0.180 |
Why?
|
| Exercise | 3 | 2024 | 538 | 0.180 |
Why?
|
| Neoplasms | 2 | 2009 | 457 | 0.180 |
Why?
|
| Radiography | 2 | 2012 | 36 | 0.180 |
Why?
|
| Taiwan | 4 | 2013 | 41 | 0.180 |
Why?
|
| Terminal Care | 1 | 2002 | 48 | 0.170 |
Why?
|
| Indinavir | 5 | 2007 | 6 | 0.170 |
Why?
|
| Reproduction | 1 | 2001 | 12 | 0.170 |
Why?
|
| Coronary Artery Disease | 2 | 2016 | 112 | 0.170 |
Why?
|
| Health Surveys | 2 | 2016 | 242 | 0.170 |
Why?
|
| Tooth Extraction | 2 | 2012 | 4 | 0.170 |
Why?
|
| Health Expenditures | 1 | 2002 | 72 | 0.170 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 10 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 259 | 0.170 |
Why?
|
| Body Weight | 4 | 2016 | 203 | 0.170 |
Why?
|
| Leptin | 2 | 2014 | 26 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 50 | 0.170 |
Why?
|
| Diet Surveys | 1 | 2010 | 56 | 0.160 |
Why?
|
| Glucocorticoids | 3 | 2012 | 23 | 0.160 |
Why?
|
| Body Height | 1 | 2020 | 61 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2012 | 197 | 0.160 |
Why?
|
| Acne Vulgaris | 1 | 2020 | 9 | 0.160 |
Why?
|
| Dyslipidemias | 2 | 2014 | 54 | 0.160 |
Why?
|
| Dopamine Agonists | 1 | 2020 | 3 | 0.160 |
Why?
|
| Risk Reduction Behavior | 2 | 2016 | 102 | 0.160 |
Why?
|
| Interviews as Topic | 3 | 2012 | 324 | 0.160 |
Why?
|
| Heart Valve Diseases | 1 | 2020 | 17 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2019 | 1 | 0.160 |
Why?
|
| Geriatrics | 1 | 2019 | 5 | 0.160 |
Why?
|
| Phosphates | 1 | 2019 | 5 | 0.160 |
Why?
|
| Calcium | 1 | 2019 | 30 | 0.150 |
Why?
|
| Levonorgestrel | 1 | 2019 | 5 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 368 | 0.150 |
Why?
|
| Progestins | 1 | 2019 | 25 | 0.150 |
Why?
|
| Comorbidity | 3 | 2017 | 552 | 0.150 |
Why?
|
| Collagen Type I | 2 | 2016 | 6 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2010 | 1107 | 0.150 |
Why?
|
| Estradiol | 1 | 2019 | 23 | 0.150 |
Why?
|
| Peptides | 2 | 2016 | 14 | 0.150 |
Why?
|
| Sex Factors | 4 | 2017 | 599 | 0.150 |
Why?
|
| Reference Values | 2 | 2016 | 86 | 0.150 |
Why?
|
| Acid-Base Equilibrium | 1 | 2019 | 1 | 0.150 |
Why?
|
| Hemodialysis, Home | 1 | 2019 | 1 | 0.150 |
Why?
|
| Bicarbonates | 1 | 2019 | 3 | 0.150 |
Why?
|
| Triiodothyronine | 1 | 2019 | 4 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2010 | 248 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2017 | 151 | 0.150 |
Why?
|
| Pyrimidinones | 4 | 2007 | 5 | 0.140 |
Why?
|
| Motor Activity | 3 | 2013 | 207 | 0.140 |
Why?
|
| Hypoparathyroidism | 1 | 1998 | 1 | 0.140 |
Why?
|
| Vocal Cord Paralysis | 1 | 1998 | 1 | 0.140 |
Why?
|
| Thyroiditis | 1 | 1998 | 2 | 0.140 |
Why?
|
| Mothers | 1 | 2009 | 105 | 0.140 |
Why?
|
| Feeding Behavior | 1 | 2009 | 163 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2018 | 13 | 0.140 |
Why?
|
| Mass Screening | 2 | 2014 | 693 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 57 | 0.140 |
Why?
|
| Bone and Bones | 2 | 2020 | 10 | 0.140 |
Why?
|
| Tunica Intima | 2 | 2011 | 10 | 0.140 |
Why?
|
| Carotid Artery Diseases | 2 | 2011 | 11 | 0.140 |
Why?
|
| Fertility | 2 | 2012 | 8 | 0.140 |
Why?
|
| Mastectomy | 1 | 2017 | 34 | 0.130 |
Why?
|
| Family Health | 1 | 2017 | 45 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 87 | 0.130 |
Why?
|
| Adiponectin | 3 | 2014 | 21 | 0.130 |
Why?
|
| Teaching Materials | 1 | 2017 | 4 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 59 | 0.130 |
Why?
|
| Ibuprofen | 1 | 2007 | 9 | 0.130 |
Why?
|
| Vestibular Diseases | 1 | 2017 | 1 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2017 | 16 | 0.130 |
Why?
|
| Allied Health Personnel | 1 | 2017 | 12 | 0.130 |
Why?
|
| Bone Diseases | 1 | 2016 | 3 | 0.130 |
Why?
|
| Bone Remodeling | 1 | 2016 | 5 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 80 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2010 | 215 | 0.130 |
Why?
|
| Health Resources | 1 | 2017 | 39 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 33 | 0.130 |
Why?
|
| Lysine | 1 | 1996 | 2 | 0.130 |
Why?
|
| Nephritis, Interstitial | 1 | 1996 | 3 | 0.130 |
Why?
|
| Fanconi Syndrome | 1 | 1996 | 4 | 0.130 |
Why?
|
| Maternal Welfare | 1 | 2006 | 12 | 0.130 |
Why?
|
| Aspirin | 1 | 2007 | 63 | 0.120 |
Why?
|
| Perinatal Care | 1 | 2006 | 12 | 0.120 |
Why?
|
| Cesarean Section | 2 | 2006 | 35 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 64 | 0.120 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2016 | 4 | 0.120 |
Why?
|
| Social Support | 2 | 2013 | 215 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 190 | 0.120 |
Why?
|
| Ergocalciferols | 2 | 2014 | 3 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2017 | 107 | 0.120 |
Why?
|
| Managed Care Programs | 1 | 2017 | 300 | 0.120 |
Why?
|
| Counseling | 1 | 2017 | 173 | 0.120 |
Why?
|
| Methimazole | 1 | 2015 | 2 | 0.110 |
Why?
|
| Propylthiouracil | 1 | 2015 | 2 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 114 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 208 | 0.110 |
Why?
|
| Life Style | 4 | 2019 | 321 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 53 | 0.110 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 38 | 0.110 |
Why?
|
| HIV Seronegativity | 3 | 2004 | 11 | 0.110 |
Why?
|
| Social Welfare | 1 | 2014 | 14 | 0.110 |
Why?
|
| Dietary Supplements | 2 | 2014 | 85 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2004 | 142 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 527 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 63 | 0.100 |
Why?
|
| Gestational Age | 2 | 2012 | 119 | 0.100 |
Why?
|
| Registries | 3 | 2016 | 475 | 0.100 |
Why?
|
| Clothing | 1 | 2013 | 1 | 0.100 |
Why?
|
| Exercise Test | 1 | 2013 | 41 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 42 | 0.100 |
Why?
|
| Ventricular Remodeling | 1 | 2013 | 6 | 0.100 |
Why?
|
| Aromatase | 2 | 2006 | 9 | 0.100 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hip | 1 | 2013 | 9 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2015 | 163 | 0.100 |
Why?
|
| Physical Examination | 1 | 2013 | 20 | 0.100 |
Why?
|
| Muscle Fatigue | 1 | 2012 | 1 | 0.100 |
Why?
|
| Health Education | 1 | 2013 | 82 | 0.090 |
Why?
|
| Gonadotropins | 1 | 2012 | 1 | 0.090 |
Why?
|
| Fertilization in Vitro | 1 | 2012 | 2 | 0.090 |
Why?
|
| Infertility | 1 | 2012 | 4 | 0.090 |
Why?
|
| Osteolysis | 1 | 2012 | 1 | 0.090 |
Why?
|
| Wound Healing | 1 | 2012 | 3 | 0.090 |
Why?
|
| Debridement | 1 | 2012 | 3 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 36 | 0.090 |
Why?
|
| Antirheumatic Agents | 1 | 2012 | 12 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 363 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 168 | 0.090 |
Why?
|
| Communication | 1 | 2013 | 181 | 0.090 |
Why?
|
| Linear Models | 3 | 2014 | 204 | 0.090 |
Why?
|
| Hormones | 1 | 2011 | 14 | 0.090 |
Why?
|
| Femoral Neck Fractures | 1 | 2011 | 1 | 0.090 |
Why?
|
| Coronary Disease | 2 | 2016 | 145 | 0.090 |
Why?
|
| Nutrition Surveys | 2 | 2023 | 55 | 0.090 |
Why?
|
| Clinical Coding | 1 | 2011 | 11 | 0.090 |
Why?
|
| Aging | 1 | 2012 | 159 | 0.090 |
Why?
|
| Dental Care | 1 | 2011 | 15 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 55 | 0.090 |
Why?
|
| Antipsychotic Agents | 1 | 2011 | 50 | 0.090 |
Why?
|
| Carotid Arteries | 1 | 2011 | 8 | 0.080 |
Why?
|
| Australia | 2 | 2024 | 26 | 0.080 |
Why?
|
| Vitamins | 1 | 2011 | 59 | 0.080 |
Why?
|
| Tooth Mobility | 1 | 2010 | 1 | 0.080 |
Why?
|
| Oral Fistula | 1 | 2010 | 1 | 0.080 |
Why?
|
| Tooth Socket | 1 | 2010 | 1 | 0.080 |
Why?
|
| Radiography, Panoramic | 1 | 2010 | 2 | 0.080 |
Why?
|
| Facial Pain | 1 | 2010 | 2 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 152 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 171 | 0.080 |
Why?
|
| Osseointegration | 1 | 2010 | 3 | 0.080 |
Why?
|
| Forecasting | 1 | 2010 | 68 | 0.080 |
Why?
|
| Etidronic Acid | 1 | 2009 | 3 | 0.080 |
Why?
|
| Technetium Compounds | 1 | 2009 | 1 | 0.080 |
Why?
|
| Imidazoles | 1 | 2009 | 4 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 5 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 13 | 0.080 |
Why?
|
| Kidney | 3 | 2014 | 52 | 0.080 |
Why?
|
| Exercise Therapy | 2 | 2018 | 75 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2015 | 13 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2009 | 36 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 2 | 2015 | 47 | 0.070 |
Why?
|
| Glucose Clamp Technique | 3 | 2007 | 17 | 0.070 |
Why?
|
| Parity | 1 | 2009 | 57 | 0.070 |
Why?
|
| Self Report | 2 | 2016 | 262 | 0.070 |
Why?
|
| New South Wales | 2 | 2018 | 2 | 0.070 |
Why?
|
| Carbamates | 1 | 2007 | 8 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2018 | 40 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2007 | 14 | 0.070 |
Why?
|
| Survival Rate | 3 | 2010 | 252 | 0.070 |
Why?
|
| Organic Cation Transporter 1 | 1 | 2007 | 1 | 0.070 |
Why?
|
| Parathyroid Hormone | 2 | 2019 | 8 | 0.070 |
Why?
|
| Demography | 2 | 2013 | 92 | 0.060 |
Why?
|
| Random Allocation | 2 | 2017 | 33 | 0.060 |
Why?
|
| Birthing Centers | 1 | 2006 | 1 | 0.060 |
Why?
|
| Virus Replication | 1 | 2007 | 12 | 0.060 |
Why?
|
| Dehydroepiandrosterone | 1 | 2007 | 7 | 0.060 |
Why?
|
| Hospitals, District | 1 | 2006 | 3 | 0.060 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2006 | 3 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2006 | 18 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 19 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2007 | 82 | 0.060 |
Why?
|
| Metformin | 1 | 2007 | 52 | 0.060 |
Why?
|
| Abdomen | 1 | 2006 | 20 | 0.060 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2006 | 3 | 0.060 |
Why?
|
| Calcinosis | 1 | 2006 | 35 | 0.060 |
Why?
|
| Estrogen Receptor beta | 1 | 2006 | 10 | 0.060 |
Why?
|
| Skinfold Thickness | 1 | 2026 | 18 | 0.060 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2006 | 34 | 0.060 |
Why?
|
| Photography | 2 | 2019 | 11 | 0.060 |
Why?
|
| Infant Formula | 1 | 2026 | 10 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 144 | 0.060 |
Why?
|
| Glyburide | 1 | 2026 | 9 | 0.060 |
Why?
|
| African Continental Ancestry Group | 1 | 2006 | 140 | 0.060 |
Why?
|
| Food Supply | 1 | 2026 | 43 | 0.060 |
Why?
|
| Lopinavir | 4 | 2007 | 5 | 0.060 |
Why?
|
| Adiposity | 1 | 2006 | 71 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 603 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2007 | 144 | 0.060 |
Why?
|
| Remission Induction | 2 | 2018 | 26 | 0.060 |
Why?
|
| Hawaii | 1 | 2025 | 62 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 302 | 0.060 |
Why?
|
| Glucose | 2 | 2002 | 30 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2015 | 19 | 0.060 |
Why?
|
| Denosumab | 1 | 2025 | 2 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2026 | 129 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2025 | 10 | 0.060 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2004 | 1 | 0.050 |
Why?
|
| Cushing Syndrome | 1 | 2004 | 2 | 0.050 |
Why?
|
| Blood Specimen Collection | 1 | 2004 | 7 | 0.050 |
Why?
|
| Longitudinal Studies | 4 | 2010 | 686 | 0.050 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 44 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 4 | 0.050 |
Why?
|
| Tunica Media | 1 | 2004 | 6 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2004 | 8 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 70 | 0.050 |
Why?
|
| Tenofovir | 1 | 2023 | 14 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2004 | 214 | 0.050 |
Why?
|
| Biomechanical Phenomena | 2 | 2013 | 6 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2023 | 19 | 0.050 |
Why?
|
| Albuminuria | 1 | 2023 | 39 | 0.050 |
Why?
|
| Meals | 1 | 2022 | 7 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2002 | 1 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 14 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2012 | 228 | 0.050 |
Why?
|
| Models, Econometric | 1 | 2002 | 9 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2016 | 226 | 0.050 |
Why?
|
| Carbohydrate Metabolism | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cost Savings | 1 | 2002 | 20 | 0.050 |
Why?
|
| Liver | 1 | 2002 | 31 | 0.050 |
Why?
|
| Hydrocortisone | 2 | 2000 | 17 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 2001 | 8 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2001 | 13 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 17 | 0.040 |
Why?
|
| Stroke | 2 | 2016 | 309 | 0.040 |
Why?
|
| Ovarian Diseases | 1 | 2001 | 1 | 0.040 |
Why?
|
| Testis | 1 | 2001 | 3 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2002 | 92 | 0.040 |
Why?
|
| Reproductive Medicine | 1 | 2001 | 2 | 0.040 |
Why?
|
| Ovary | 1 | 2001 | 5 | 0.040 |
Why?
|
| Hypogonadism | 1 | 2001 | 5 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 90 | 0.040 |
Why?
|
| Hyperandrogenism | 1 | 2001 | 1 | 0.040 |
Why?
|
| Genitalia | 1 | 2001 | 2 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 2001 | 4 | 0.040 |
Why?
|
| Infertility, Female | 1 | 2001 | 11 | 0.040 |
Why?
|
| Health Services Research | 1 | 2002 | 201 | 0.040 |
Why?
|
| Time | 1 | 2020 | 20 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 30 | 0.040 |
Why?
|
| Diet Records | 1 | 2010 | 37 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 154 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 346 | 0.040 |
Why?
|
| Energy Intake | 1 | 2010 | 97 | 0.040 |
Why?
|
| Educational Status | 1 | 2010 | 177 | 0.040 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2014 | 12 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Benign Paroxysmal Positional Vertigo | 1 | 2019 | 1 | 0.040 |
Why?
|
| Triglycerides | 2 | 2014 | 81 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 50 | 0.040 |
Why?
|
| Minerals | 1 | 2019 | 7 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 24 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 79 | 0.040 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2019 | 3 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2009 | 26 | 0.040 |
Why?
|
| Disorders of Sex Development | 1 | 1999 | 1 | 0.040 |
Why?
|
| Virilism | 1 | 1999 | 2 | 0.040 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2019 | 21 | 0.040 |
Why?
|
| Prednisone | 1 | 1999 | 6 | 0.040 |
Why?
|
| Androgens | 1 | 1999 | 14 | 0.040 |
Why?
|
| Acidosis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2019 | 3 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2019 | 32 | 0.040 |
Why?
|
| Lipodystrophy | 1 | 1998 | 1 | 0.040 |
Why?
|
| Lipomatosis | 1 | 1998 | 1 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 402 | 0.040 |
Why?
|
| Vestibule, Labyrinth | 1 | 2018 | 1 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2018 | 24 | 0.040 |
Why?
|
| Prednisolone | 1 | 1998 | 4 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2018 | 45 | 0.040 |
Why?
|
| Back | 1 | 1998 | 1 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 1998 | 5 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 104 | 0.030 |
Why?
|
| Prenatal Care | 1 | 1999 | 129 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1998 | 107 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1997 | 4 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1997 | 15 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2007 | 12 | 0.030 |
Why?
|
| Therapeutics | 1 | 2017 | 1 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 8 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 5 | 0.030 |
Why?
|
| New Zealand | 1 | 2017 | 7 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2019 | 115 | 0.030 |
Why?
|
| Systole | 1 | 2017 | 21 | 0.030 |
Why?
|
| Minnesota | 1 | 2017 | 51 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 27 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 10 | 0.030 |
Why?
|
| Premenopause | 1 | 2016 | 24 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 6 | 0.030 |
Why?
|
| Menstruation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 1996 | 7 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 50 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 166 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 323 | 0.030 |
Why?
|
| Colorado | 1 | 2017 | 170 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 74 | 0.030 |
Why?
|
| Research Design | 2 | 2011 | 337 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 61 | 0.030 |
Why?
|
| Anxiety | 1 | 2017 | 162 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 148 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 161 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 177 | 0.030 |
Why?
|
| Venules | 1 | 2014 | 1 | 0.030 |
Why?
|
| Arterioles | 1 | 2014 | 2 | 0.030 |
Why?
|
| Retinal Artery | 1 | 2014 | 2 | 0.030 |
Why?
|
| Retinal Vein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 7 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cholecalciferol | 1 | 2014 | 16 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2004 | 42 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 120 | 0.030 |
Why?
|
| Foot | 1 | 2013 | 4 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2013 | 3 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 9 | 0.030 |
Why?
|
| Environment | 1 | 2013 | 50 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 384 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2012 | 4 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2012 | 18 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 73 | 0.020 |
Why?
|
| Proteinuria | 1 | 2012 | 26 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2012 | 7 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2012 | 13 | 0.020 |
Why?
|
| Depression | 1 | 2017 | 507 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 319 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2013 | 109 | 0.020 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 96 | 0.020 |
Why?
|
| Infant Food | 1 | 2011 | 7 | 0.020 |
Why?
|
| Physicians | 1 | 2013 | 120 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2011 | 7 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 89 | 0.020 |
Why?
|
| World Health Organization | 1 | 2011 | 10 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 34 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 268 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 298 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 2010 | 3 | 0.020 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2010 | 5 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2011 | 213 | 0.020 |
Why?
|
| Health Maintenance Organizations | 1 | 2011 | 403 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 53 | 0.020 |
Why?
|
| Geography | 1 | 2008 | 38 | 0.020 |
Why?
|
| Furans | 1 | 2007 | 1 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2007 | 48 | 0.020 |
Why?
|
| Clone Cells | 1 | 2007 | 1 | 0.020 |
Why?
|
| 3T3-L1 Cells | 1 | 2007 | 2 | 0.020 |
Why?
|
| Cell Line | 1 | 2007 | 11 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2007 | 14 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 20 | 0.020 |
Why?
|
| Mice | 1 | 2007 | 82 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 61 | 0.020 |
Why?
|
| Biological Availability | 1 | 2007 | 2 | 0.020 |
Why?
|
| Health Facility Size | 1 | 2006 | 2 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2006 | 19 | 0.020 |
Why?
|
| National Health Programs | 1 | 2006 | 12 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2007 | 48 | 0.020 |
Why?
|
| Birth Certificates | 1 | 2006 | 24 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2006 | 14 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2006 | 85 | 0.020 |
Why?
|
| Animals | 1 | 2007 | 285 | 0.020 |
Why?
|
| Viral Load | 1 | 2007 | 110 | 0.020 |
Why?
|
| Length of Stay | 1 | 2006 | 182 | 0.010 |
Why?
|
| Cause of Death | 1 | 2006 | 179 | 0.010 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2004 | 1 | 0.010 |
Why?
|
| Petrosal Sinus Sampling | 1 | 2004 | 1 | 0.010 |
Why?
|
| Pituitary Neoplasms | 1 | 2004 | 2 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 10 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 2004 | 2 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 34 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 25 | 0.010 |
Why?
|
| Inflammation | 1 | 2004 | 60 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2003 | 20 | 0.010 |
Why?
|
| Adenoma | 1 | 2004 | 98 | 0.010 |
Why?
|
| Leukopoiesis | 1 | 2002 | 1 | 0.010 |
Why?
|
| Gluconeogenesis | 1 | 2002 | 1 | 0.010 |
Why?
|
| Lipolysis | 1 | 2002 | 3 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 181 | 0.010 |
Why?
|
| Smoking | 1 | 2004 | 420 | 0.010 |
Why?
|
| HIV Wasting Syndrome | 1 | 2001 | 1 | 0.010 |
Why?
|
| Testosterone | 1 | 2000 | 21 | 0.010 |
Why?
|
| Health Status | 1 | 2001 | 291 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1997 | 2 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1997 | 14 | 0.010 |
Why?
|
| Pedigree | 1 | 1997 | 65 | 0.010 |
Why?
|